Visium, an AI firm specializing in regulated industries, has successfully completed its first institutional funding round, marking a significant milestone after eight years of self-funding. With a workforce of 100 across Europe, the company aims to expand its operations in both Europe and the United States.
Founded in 2018 in Lausanne, Visium combines consulting and software solutions tailored for life sciences and specialty chemicals. The company has executed over 250 AI and data projects, serving notable clients such as Roche, Novartis, and DSM-Firmenich. The recent funding round, co-led by Columbus Venture Partners and Concentric, includes contributions from prominent angel investors, although the total amount raised remains undisclosed.
Columbus Venture Partners, based in Valencia, focuses on biotechnology and life sciences with over €800 million in assets under management, while Concentric is known for its investments in transformative software companies. This strategic funding is expected to enhance Visium's team and product offerings significantly.
CEO Alen Arslanagic emphasized that the funding is not just about capital; it’s about forming partnerships with investors who share Visium's vision. The company also appointed four new directors to its board and expanded its advisory board with seasoned professionals from the pharma and biotech sectors, indicating a robust plan for future growth and innovation in AI applications within life sciences.